NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
This article was originally published in The Tan Sheet
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing
You may also be interested in...
Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee
The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery
NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter